Hologic (NASDAQ:HOLX) Stock Rating Lowered by Wall Street Zen

Key Points

• Hologic's stock rating was downgraded from "buy" to "hold" by analysts at Wall Street Zen, indicating a more cautious outlook on the stock's performance.
• Despite the downgrade, several analysts have reported increased price targets for Hologic, with Evercore ISI raising their target from $62.00 to $68.00 and UBS Group raising from $65.00 to $70.00.
• Hologic reported a quarterly EPS of $1.08, surpassing analyst expectations, with revenue reaching $1.02 billion and showing a 1.2% year-over-year growth.

Hologic (NASDAQ:HOLX - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued on Saturday.

HOLX has been the topic of a number of other reports. Argus raised shares of Hologic from a "hold" rating to a "buy" rating and set a $80.00 target price on the stock in a report on Monday, August 18th. Royal Bank Of Canada upgraded shares of Hologic from a "sector perform" rating to an "outperform" rating and lifted their price target for the stock from $72.00 to $87.00 in a report on Wednesday, August 6th. Needham & Company LLC restated a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Mizuho set a $75.00 target price on Hologic in a research report on Thursday, July 31st. Finally, Morgan Stanley lifted their target price on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $78.00.

Hologic Price Performance

NASDAQ:HOLX traded up $0.15 on Friday, hitting $66.39. The company had a trading volume of 1,633,745 shares, compared to its average volume of 1,584,991. The firm has a 50 day moving average of $66.31 and a two-hundred day moving average of $62.59. The stock has a market capitalization of $14.77 billion, a price-to-earnings ratio of 27.55, a PEG ratio of 2.40 and a beta of 0.57. Hologic has a 52 week low of $51.90 and a 52 week high of $84.39. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.03. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company's revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period in the prior year, the business earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, research analysts anticipate that Hologic will post 4.28 earnings per share for the current year.

Institutional Trading of Hologic

A number of hedge funds and other institutional investors have recently bought and sold shares of HOLX. Osaic Holdings Inc. raised its holdings in shares of Hologic by 22.7% in the 2nd quarter. Osaic Holdings Inc. now owns 20,163 shares of the medical equipment provider's stock worth $1,310,000 after acquiring an additional 3,736 shares during the last quarter. CYBER HORNET ETFs LLC bought a new position in Hologic during the 2nd quarter valued at $40,000. Headlands Technologies LLC boosted its holdings in Hologic by 2.6% during the 2nd quarter. Headlands Technologies LLC now owns 40,380 shares of the medical equipment provider's stock worth $2,631,000 after acquiring an additional 1,036 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its stake in shares of Hologic by 23.1% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 351,042 shares of the medical equipment provider's stock worth $22,903,000 after acquiring an additional 65,848 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Hologic by 40.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,048 shares of the medical equipment provider's stock valued at $264,000 after purchasing an additional 1,157 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.